Search

Your search keyword '"Favre, Claudio"' showing total 36 results
Start Over Author "Favre, Claudio" Publication Year Range Last 3 years
36 results on '"Favre, Claudio"'

3. Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Children with High-Risk Neuroblastoma Using a Reduced-Intensity Conditioning Regimen: Results from the AIEOP Trial

Author

Prete, Arcangelo, primary, Lanino, Edoardo, additional, Saglio, Francesco, additional, Biffi, Alessandra, additional, Calore, Elisabetta, additional, Faraci, Maura, additional, Rondelli, Roberto, additional, Favre, Claudio, additional, Zecca, Marco, additional, Casazza, Gabriella, additional, Porta, Fulvio, additional, Luksch, Roberto, additional, Cesaro, Simone, additional, Rabusin, Marco, additional, Parasole, Rosanna, additional, Mura, Rosa Maria, additional, Lo Nigro, Luca, additional, Leardini, Davide, additional, Pagliara, Daria, additional, Locatelli, Franco, additional, and Fagioli, Franca, additional

Published
2024
Full Text
View/download PDF

6. Healthcare migration in Italian paediatric haematology-oncology centres belonging to AIEOP

Author

Rondelli, Roberto, primary, Belotti, Tamara, additional, Masetti, Riccardo, additional, Locatelli, Franco, additional, Massimino, Maura, additional, Biffi, Alessandra, additional, Dufour, Carlo, additional, Fagioli, Franca, additional, Menna, Giuseppe, additional, Biondi, Andrea, additional, Favre, Claudio, additional, Zecca, Marco, additional, Santoro, Nicola, additional, Russo, Giovanna, additional, Perrotta, Silverio, additional, Pession, Andrea, additional, and Prete, Arcangelo, additional

Published
2024
Full Text
View/download PDF

7. Healthcare migration in Italian paediatric haematology-oncology centres belonging to AIEOP.

Author

Rondelli, Roberto, primary, Belotti, Tamara, additional, Masetti, Riccardo, additional, Locatelli, Franco, additional, Massimino, Maura, additional, Biffi, Alessandra, additional, Dufour, Carlo, additional, Fagioli, Franca, additional, Menna, Giuseppe, additional, Biondi, Andrea, additional, Favre, Claudio, additional, Zecca, Marco, additional, Santoro, Nicola, additional, Russo, Giovanna, additional, Perrotta, Silverio, additional, Pession, Andrea, additional, and Prete, Arcangelo, additional

Published
2023
Full Text
View/download PDF

8. Approaching hemophagocytic lymphohistiocytosis.

Author

Chinnici, Aurora, Beneforti, Linda, Pegoraro, Francesco, Trambusti, Irene, Tondo, Annalisa, Favre, Claudio, Coniglio, Maria Luisa, and Sieni, Elena

Subjects
HEMOPHAGOCYTIC lymphohistiocytosis, NUCLEOTIDE sequencing, MACROPHAGE activation syndrome, SYMPTOMS, CLINICAL pathology, DISEASE progression
Abstract

Hemophagocytic Lymphohistiocytosis (HLH) is a rare clinical condition characterized by sustained but ineffective immune system activation, leading to severe and systemic hyperinflammation. It may occur as a genetic or sporadic condition, often triggered by an infection. The multifaceted pathogenesis results in a wide range of non-specific signs and symptoms, hampering early recognition. Despite a great improvement in terms of survival in the last decades, a considerable proportion of patients with HLH still die from progressive disease. Thus, prompt diagnosis and treatment are crucial for survival. Faced with the complexity and the heterogeneity of syndrome, expert consultation is recommended to correctly interpret clinical, functional and genetic findings and address therapeutic decisions. Cytofluorimetric and genetic analysis should be performed in reference laboratories. Genetic analysis is mandatory to confirm familial hemophagocytic lymphohistiocytosis (FHL) and Next Generation Sequencing is increasingly adopted to extend the spectrum of genetic predisposition to HLH, though its results should be critically discussed with specialists. In this review, we critically revise the reported laboratory tools for the diagnosis of HLH, in order to outline a comprehensive and widely available workup that allows to reduce the time between the clinical suspicion of HLH and its final diagnosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Inside the Biology of the β3-Adrenoceptor.

Author

Pasha, Amada, Tondo, Annalisa, Favre, Claudio, and Calvani, Maura

Subjects
BIOLOGY, WHITE adipose tissue, BROWN adipose tissue, TUMOR growth, BLADDER
Abstract

Since the first discovery in 1989, the β3-adrenoceptor (β3-AR) has gained great attention because it showed the ability to regulate many physiologic and metabolic activities, such as thermogenesis and lipolysis in brown and white adipose tissue, respectively (BAT, WAT), negative inotropic effects in cardiomyocytes, and relaxation of the blood vessels and the urinary bladder. The β3-AR has been suggested as a potential target for cancer treatment, both in adult and pediatric tumors, since under hypoxia its upregulation in the tumor microenvironment (TME) regulates stromal cell differentiation, tumor growth and metastases, signifying that its agonism/antagonism could be useful for clinical benefits. Promising results in cancer research have proposed the β3-AR being targeted for the treatment of many conditions, with some drugs, at present, undergoing phase II and III clinical trials. In this review, we report the scientific journey followed by the research from the β3-Ars' discovery, with focus on the β3-Ars' role in cancer initiation and progression that elects it an intriguing target for novel antineoplastic approaches. The overview highlights the great potential of the β3-AR, both in physiologic and pathologic conditions, with the intention to display the possible benefits of β3-AR modulation in cancer reality. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma

Author

Nastasi, Nicoletta, primary, Pasha, Amada, additional, Bruno, Gennaro, additional, Subbiani, Angela, additional, Pietrovito, Laura, additional, Leo, Angela, additional, Scala, Lucia, additional, de Simone, Lorena, additional, Casazza, Gabriella, additional, Lunardi, Federica, additional, Taddei, Maria Letizia, additional, Tamburini, Angela, additional, Tondo, Annalisa, additional, Favre, Claudio, additional, and Calvani, Maura, additional

Published
2023
Full Text
View/download PDF

11. Approaching hemophagocytic lymphohistiocytosis

Author

Chinnici, Aurora, primary, Beneforti, Linda, additional, Pegoraro, Francesco, additional, Trambusti, Irene, additional, Tondo, Annalisa, additional, Favre, Claudio, additional, Coniglio, Maria Luisa, additional, and Sieni, Elena, additional

Published
2023
Full Text
View/download PDF

19. Isolated Full Donor T-Cell Chimerism After Haploidentical TCRαβ/CD19 Depleted HSCT Maintains Remission of Familial HLH.

Author

Consonni, Filippo, Coniglio, Maria Luisa, Florence HLH consortium, Martini, Beatrice, Santoro, Rosalba, Chinnici, Aurora, Beneforti, Linda, Allegro, Elisa, Bambi, Franco, Brugnolo, Francesca, Cuzzubbo, Daniela, Ermini, Stefano, Frenos, Stefano, Pegoraro, Francesco, Sanvito, Maria Chiara, Tintori, Veronica, Trambusti, Irene, Favre, Claudio, Sieni, Elena, and Gambineri, Eleonora

Published
2024
Full Text
View/download PDF

20. Whole‐body magnetic resonance imaging for staging Langerhans cell histiocytosis in children and young adults

Author

Perrone, Anna, primary, Lakatos, Karoly, additional, Pegoraro, Francesco, additional, Trambusti, Irene, additional, Fotzi, Ilaria, additional, Selvi, Valeria, additional, Prosch, Helmut, additional, Sertorio, Fiammetta, additional, Pötschger, Ulrike, additional, Favre, Claudio, additional, Conte, Massimo, additional, Minkov, Milen, additional, and Sieni, Elena, additional

Published
2022
Full Text
View/download PDF

25. Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL).

Author

Keating Franklin, Anna Rachel, primary, Luisi, Flavio, additional, Pianovski, Mara, additional, Salvino, Marco Aurelio, additional, Fagioli, Franca, additional, Epelman, Sidnei, additional, Lima, Luciana, additional, Norris, Robin Elizabeth, additional, Odone-Filho, Vicente, additional, Zecca, Marco, additional, Favre, Claudio, additional, Kobayashi, Ryoji, additional, Koga, Yuhki, additional, Sidi, Yulia, additional, Zhou, Xiaofei, additional, Bai, Xiang, additional, Campana, Frank, additional, Leonard, E. Jane, additional, and Locatelli, Franco, additional

Published
2022
Full Text
View/download PDF

26. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study

Author

Cerrano, Marco, Bonifacio, Massimiliano, Olivi, Matteo, Curti, Antonio, Malagola, Michele, Dargenio, Michelina, Scattolin, Anna Maria, Papayannidis, Cristina, Forghieri, Fabio, Gurrieri, Carmela, Tanasi, Ilaria, Zappasodi, Patrizia, La Starza, Roberta, Fracchiolla, Nicola Stefano, Chiusolo, Patrizia, Giaccone, Luisa, Del Principe, Maria Ilaria, Giglio, Fabio, Defina, Marzia, Favre, Claudio, Rizzari, Carmelo, Castella, Barbara, Pizzolo, Giovanni, Ferrara, Felicetto, Chiaretti, Sabina, and Foà, Robin

Subjects
Not available, Settore MED/15
Published
2022

29. Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS‐2)

Author

Palmerini, Emanuela, primary, Meazza, Cristina, additional, Tamburini, Angela, additional, Bisogno, Gianni, additional, Ferraresi, Virginia, additional, Asaftei, Sebastian D., additional, Milano, Giuseppe M., additional, Coccoli, Luca, additional, Manzitti, Carla, additional, Luksch, Roberto, additional, Serra, Massimo, additional, Gambarotti, Marco, additional, Donati, Davide M., additional, Scotlandi, Katia, additional, Bertulli, Rossella, additional, Favre, Claudio, additional, Longhi, Alessandra, additional, Abate, Massimo E., additional, Perrotta, Silverio, additional, Mascarin, Maurizio, additional, D’Angelo, Paolo, additional, Cesari, Marilena, additional, Staals, Eric L., additional, Marchesi, Emanuela, additional, Carretta, Elisa, additional, Ibrahim, Toni, additional, Casali, Paolo G., additional, Picci, Piero, additional, Fagioli, Franca, additional, and Ferrari, Stefano, additional

Published
2022
Full Text
View/download PDF

30. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, Marco, primary, Bonifacio, Massimiliano, additional, Olivi, Matteo, additional, Curti, Antonio, additional, Malagola, Michele, additional, Dargenio, Michelina, additional, Scattolin, Anna Maria, additional, Papayannidis, Cristina, additional, Forghieri, Fabio, additional, Gurrieri, Carmela, additional, Tanasi, Ilaria, additional, Zappasodi, Patrizia, additional, La Starza, Roberta, additional, Fracchiolla, Nicola Stefano, additional, Chiusolo, Patrizia, additional, Giaccone, Luisa, additional, Del Principe, Maria Ilaria, additional, Giglio, Fabio, additional, Defina, Marzia, additional, Favre, Claudio, additional, Rizzari, Carmelo, additional, Castella, Barbara, additional, Pizzolo, Giovanni, additional, Ferrara, Felicetto, additional, Chiaretti, Sabina, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

31. Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study

Author

Schiavo, Ebe, primary, Martini, Beatrice, additional, Attardi, Enrico, additional, Consonni, Filippo, additional, Ciullini Mannurita, Sara, additional, Coniglio, Maria Luisa, additional, Tellini, Marco, additional, Chiocca, Elena, additional, Fotzi, Ilaria, additional, Luti, Laura, additional, D’Alba, Irene, additional, Veltroni, Marinella, additional, Favre, Claudio, additional, and Gambineri, Eleonora, additional

Published
2022
Full Text
View/download PDF

34. Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP)

Author

Zecca, Marco, Ferrari, Andrea, Quarello, Paola, Rabusin, Marco, Balduzzi, Adriana, Buldini, Barbara, Rostagno, Elena, Prete, Arcangelo, Favre, Claudio, Massimino, Maura, Biondi, Andrea, Porta, Fulvio, Biffi, Alessandra, Locatelli, Franco, Pession, Andrea, and Fagioli, Franca

Abstract

This article reviews the primary goals and achievements of the Italian Association for Pediatric Hematology-Oncology (Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP]), a national cooperative group that has been working for children and adolescents with cancer in Italy since 1975.

Published
2021
Full Text
View/download PDF

35. Outcome of primary hemophagocytic lymphohistiocytosis: a report on 143 patients from the Italian Registry.

Author

Pegoraro F, Chinnici A, Beneforti L, Tanturli M, Trambusti I, De Fusco C, Micalizzi C, Barat V, Cesaro S, Gaspari S, Dell'Acqua F, Todesco A, Timeus F, Aricò M, Favre C, Tondo A, Coniglio ML, Sieni E, and Working Group AH

Subjects
Humans, Italy epidemiology, Male, Female, Infant, Child, Preschool, Child, Treatment Outcome, Adolescent, Prognosis, Combined Modality Therapy, Follow-Up Studies, Lymphohistiocytosis, Hemophagocytic mortality, Lymphohistiocytosis, Hemophagocytic therapy, Lymphohistiocytosis, Hemophagocytic diagnosis, Registries, Hematopoietic Stem Cell Transplantation
Abstract

Primary hemophagocytic lymphohistiocytosis (pHLH) is a severe, life-threatening hyperinflammatory syndrome caused by defects in genes of the granule-dependent cytotoxic pathway. Here we investigated the clinical presentation and outcome in a large cohort of 143 patients with pHLH diagnosed in the last 15 years and enrolled in the Italian registry. The median age at diagnosis was 12 months (interquartile range, 2-81), and 92 patients (64%) fulfilled the HLH-2004 criteria. Of 111 patients who received first-line combined therapy (HLH-94, HLH-2004, Euro-HIT protocols), 65 (59%) achieved complete response and 21 (19%) partial response. Thereafter, 33 patients (30%) reactivated, and 92 (64%) received hematopoietic stem cell transplantation, 78 of whom (85%) survived and were alive at a median follow-up from diagnosis of 67 months. Thirty-six patients (25%) died before hematopoietic stem cell transplantation and 14 (10%) after. Overall, 93 patients (65%) were alive after a median follow-up of 30 months. Unadjusted predictors of non-response were age <6 months and high ferritin and bilirubin levels, while predictors of pre-transplant and overall mortality were high ferritin and bilirubin levels. At multivariable analysis, high levels of ferritin predicted non-response, while high levels of bilirubin predicted pre-transplant and overall mortality. Despite recent advances in therapeutic management, pHLH remains a life-threatening condition with significant early mortality. Liver dysfunction is the main predictor of poor prognosis.

Published
2024
Full Text
View/download PDF

36. Case Report: Clinical and Hematological Characteristics of ε γδβ Thalassemia in an Italian Patient.

Author

Fotzi I, Pegoraro F, Chiocca E, Casini T, Mogni M, Veltroni M, and Favre C

Abstract

Introduction: ε γδβ thalassemia is a rare form of β-thalassemia mostly described in children originating from Northern Europe. Only anecdotic cases from the Mediterranean area are reported. The diagnosis is challenging, considering the rarity of the disease and its heterogeneous clinical presentation. Most patients have neonatal microcytic anemia, sometimes requiring in utero and/or neonatal transfusions, and typically improving with age., Case Description: We report on an Italian newborn presenting with severe neonatal anemia that required red blood cell transfusion. After the first months of life, hemoglobin levels improved with residual very low mean corpuscular volume. β and α thalassemia, IRIDA syndrome, and sideroblastic anemia were excluded. Finally, a diagnosis of ε γδβ thalassemia was made after microarray analysis of single nucleotide polymorphisms revealed a 26 kb single copy loss of chromosome 11p15.4, including the HBD, HBBP1, HBG1, and HBB genes., Conclusions: Despite its rarity, the diagnosis of ε γδβ thalassemia should be considered in newborns with severe neonatal anemia requiring in utero and/or neonatal transfusions, but also in older infants with microcytic anemia, after excluding more prevalent red blood cell disorders., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Fotzi, Pegoraro, Chiocca, Casini, Mogni, Veltroni and Favre.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results